Lipocine misses primary endpoint in Phase 3 PPD trial but cites data anomaly

Lipocine reported that its oral brexanolone candidate for postpartum depression failed to meet its primary endpoint in a recent Phase 3 study. However, management suggested excluding an anomaly at one site would validate the drug's efficacy and plans new clinical studies and regulatory meetings.